NCT02954991 2024-04-22
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2 Terminated
Clinical Trials
8 trialsNCT02236195 2017-09-01
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Mirati Therapeutics Inc.
Phase 2 Completed
NCT00358982 2015-07-03
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00359086 2015-07-01
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Mirati Therapeutics Inc.
Phase 2 Completed
NCT00374296 2015-07-01
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00431873 2015-07-01
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Phase 2 Completed
NCT00543582 2015-07-01
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00666497 2015-05-08
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc.
Phase 2 Terminated